ClinicalTrials.gg
RecruitingNCT06538077HERBUpdated Nov 17, 2026

BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE

A Phase 4 interventional study of Oral Branched chain Amino acid and Rifaximin 550 MG in Hepatic Encephalopathy, Decompensated Cirrhosis and Minimal Hepatic Encephalopathy, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 17, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.

Planned enrollment
Largest of 18
336 · median 94
Started
2025
the only one that year
Phase 4
8 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Post Graduate Institute of Medical Education and Research, Chandigarh

Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one has the largest planned enrollment, is the only one that started in 2025, is one of 8 in phase 4, and was the 18th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rifaximin in Hepatic Encephalopathy, or all of them as a file.
02

Study summary

Rationale

  • Patients who recover from an episode of overt HE(OHE) are at risk of recurrent episodes of HE and persistent minimal hepatic encephalopathy, impacting their daily functioning and mental health.
  • A multicentric pan-India team will evaluate the role of oral branched-chain amino acids (BCAA) vs Rifaximin as secondary prophylaxis following overt HE as compared with improvement in cognitive function.

Novelty:

  • This study is intended to investigate the role of BCAA vs rifaximin as the ideal second-line therapy for HE management, recurrence, and overall health, including cognitive function, depression and anxiety.
  • The head-to-head comparison of BCAA+lactulose+ pill-placebo vs rifaximin+ lactulose+ powder-placebo ensures minimization of bias and has adequate power to determine rates of recurrence,

Objectives:

  • To assess the 1st breakthrough episode of HE during 6months in BCAA vs rifaximin groups as ideal secondary prophylaxis in HE. Methodology
  • Double-blind placebo-controlled double-dummy randomized trial of BCAA supplementation vs rifaximin as the ideal second-line therapy in patients with cirrhosis who have recovered from an episode of OHE. Expected Outcome
  • Ideal second line agent HE prophylaxis (rifaximin or BCAA) following 1st line lactulose is unclear in an Indian context where dysbiosis and sarcopenia are prevalent, and cost of therapy needs to be optimized.
  • Optimal HE management prevents recurrence episodes of HE, and improves prognosis, neurocognitive function, and overall health-related quality of life(HRQOL).
  • Creation of a management algorithm based deductive models incorporating etiology and severity of liver disease, cognitive performance, sarcopenia, and ammonia, and neuropsychiatric impact of using BCAA vs Rifaximin will be created.
Read the detailed description

Hepatic encephalopathy (HE), a complex neuropsychiatric syndrome arising from liver dysfunction and the establishment of portosystemic shunts (PSS), presents a significant clinical challenge, marked by a spectrum of cognitive, emotional, and motor disturbances. These conditions necessitate precise diagnostic and therapeutic approaches to mitigate its impact on patient well-being and quality of life.

  • The prevalence of OHE at the time of diagnosis of cirrhosis is 10%-14% in general, 16%-21% in those with decompensated cirrhosis. The cumulated numbers indicate that OHE will occur in 30%-40% of those with cirrhosis at some time during their clinical course and in the survivors in most cases repeatedly. Minimal HE (MHE) or covert HE (CHE) occurs in 20%-80% of patients with cirrhosis. This high incidence rate calls for effective, accessible, and cost-efficient treatment modalities to improve patient outcomes and quality of life.
  • Indian patients have sarcopenia and reduced muscle strength impairing peripheral ammonia metabolism, and also have gut dysbiosis which can predispose to another episode of HE. A critical initial step in addressing HE involves the identification of precipitating factors, with evidence suggesting that reversible elements contribute to over 80% of HE cases.
  • Current therapeutic interventions primarily target the reduction of blood ammonia levels, yet the effectiveness of these treatments varies, underscoring the necessity for ongoing research and innovation in HE management.
  • Patients recovering from OHE are at risk of recurrent episodes and may suffer from persistent MHE, a condition often undiagnosed due to its subtle cognitive manifestations. Such individuals may have cognitive impairment that affect patients' daily functioning and mental health, necessitating the development of standardized diagnostic psychometric tests protocols tailored to diverse populations.
  • Mainstay for treatment of HE has been lactulose or lactitol. How lactulose acts in HE has been a matter of debate and various hypotheses have been postulated. Inglefenger et al., suggested it to be due to proliferation of Lactobacillus with inhibition of Bacteroides and other organisms (28). Lactulose has pleiotropic effects, and reduction of ammonia is only one of the ways in which it acts on HE.
  • Rifaximin is an oral antibiotic having \<0.4% of systemic absorption. It acts against coliforms like Escherichia coli and plays a role in the reduction of ammonia levels and prevention of recurrence of HE . Several trials have compared Rifaximin as a therapy of HE with placebo, neomycin and non-absorbable disaccharides . Rifaximin emerged as a promising alternative, showing comparable efficacy in managing OHE and preventing its recurrence..
  • This is a double-blind, randomized placebo-controlled trial of branched-chain amino acid supplementation vs rifaximin as the ideal second-line therapy in patients with cirrhosis who have recovered from an episode of overt hepatic encephalopathy, with either drug given over 12 weeks with endpoints being prevention of recurrence of another episode of HE, efficacy, safety, and improvement in neurocognitive function
03

Conditions studied

  • Hepatic Encephalopathy
  • Decompensated Cirrhosis
  • Minimal Hepatic Encephalopathy

Keywords

  • Hepatic encephalopathy
  • Branched-chain amino acids
  • Computerized neurocognitive test battery
  • Double blind placebo controlled multicentric randomized controlled trial
  • rifaximin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cirrhosis defined by standard clinical, ultrasonographic findings and/or histological criteria. Cirrhosis of any etiology may be included. However, patients with cirrhosis due to hepatitis must be on stable doses for ≥3-month period before study inclusion; those with viral hepatitis, must similarly be on anti-viral therapy with controlled viremia or with SVR.
  2. Any gender
  3. Discharged from the hospital following an episode of overt hepatic encephalopathy.
  4. Participants able to give

Exclusion criteria

Exclusion Criteria:

  1. Subjects with active bacterial or fungal infection
  2. Subjects with active or very recent gastrointestinal bleeding in the last 2 weeks.
  3. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification.
  4. Conditions that can impact interpretation of cognitive function:

    i) Untreated viremic virus infection ii) Established neurological/degenerative disorders iii) Patient undergoing active alcohol withdrawal treatment Iv) Patient is intoxicated or under the influence of illicit drugs as per clinician assessment V) Treatment with antipsychotics or other psychotropic drugs with sedative effects

  5. Patients with active hepatocellular carcinoma or history of hepatocellular carcinoma that is in remission for less than six months.
  6. Patients with a history of significant extrahepatic disease with impaired short-term prognosis, including: i) Congestive heart failure Grade III/IV or \<30% ii) : GOLD >2, ii) Chronic kidney disease with serum creatinine >2mg/dL or under renal replacement therapy.
  7. Patients with current extra hepatic , including solid tumours and hematologic disorders.
  8. Patients with MELD>20
  9. Patients with mental incapacity, or those unlikely to survive 12 weeks or any other reason considered by the investigator precluding adequate understanding, cooperation, or compliance in the study activities.
  10. Patients with TIPS shunt in situ
  11. Pregnancy (urine pregnancy test at inclusion)
  12. Refusal or inability to give
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    A1=Experimental:

    Drug: Oral BCAA + Rifaximin placebo + Lactulose ( Oral BCAA 15 gm in once daily dose With Lactulose for 12 weeks)

    Drug: Oral Branched chain Amino acid · Drug: Lactulose · Drug: Placebo for Rifaximin 550mg

  • Experimental
    A2= Experimental:

    Drug: Rifaximin+ BCAA Placebo + Lactulose ( Oral Rifaximin 550 mg twice daily daily + Lactulose therapy for 12 weeks)

    Drug: Rifaximin 550 MG · Drug: Lactulose · Drug: Placebo for BCAA

Interventions

  • DrugAmino Acids, Branched-ChainStudies of Amino Acids, Branched-ChainAmino Acids, Branched-Chain pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 12 weeks

  • DrugRifaximinStudies of RifaximinRifaximin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 12 weeks

  • Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day

  • DrugPlacebo for BCAA

    A placebo comparator of 15 gm of skimmed milk powder will be used.

  • DrugPlacebo for Rifaximin 550mg

    Identical placebo sugar pills will be used as a placebo.

06

What researchers measure

Primary outcomes

  1. Number of breakthrough event of overt hepatic encephalopathy in BCAA vs rifaximin arm

    Time to a breakthrough overt HE episode will be the duration (number of days) from time of first dose of study drug to the first breakthrough overt HE episode. The number of events of a first breakthrough overt HE episode during the treatment period will be assessed

    Time frame: 24 Weeks

Secondary outcomes

  1. Computerized Cognitive Test battery for Cognitive performance

    A curated Computer based Cognitive test battery has been created for this protocol with a fixed set of tasks comprising Animal Naming Test, reaction times, digit span and number connection tests. This has been designed using the PEBL opensource language. Psychology Experiment Building Language. \[2019-03\] PEBL Version 2.1. The battery has been validated by us previously in patients with chronic hepatitis C infection.

    Time frame: At Enrolment

  2. Computerized Cognitive Test battery for Cognitive performance

    Computerized Cognitive Test battery: A curated Computer based Cognitive test battery has been created for this protocol with a fixed set of tasks comprising Animal Naming Test, reaction times, digit span and number connection tests. This has been designed using the PEBL opensource language. Psychology Experiment Building Language. \[2019-03\] PEBL Version 2.1. The battery has been validated by us previously in patients with chronic hepatitis C infection.

    Time frame: 30 days

  3. Computerized Cognitive Test battery for Cognitive performance

    Computerized Cognitive Test battery A curated Computer based Cognitive test battery has been created for this protocol with a fixed set of tasks comprising Animal Naming Test, reaction times, digit span and number connection tests. This has been designed using the PEBL opensource language. Psychology Experiment Building Language. \[2019-03\] PEBL Version 2.1. The battery has been validated by us previously in patients with chronic hepatitis C infection.

    Time frame: 90 days

  4. Psychiatric Assessment

    Beck's Depression Inventory (BDI) test will be performed. The scoring is as follows 1-10: These ups and downs are considered normal 11-16: Mild mood disturbance 17-20: Borderline clinical depression 21-30: Moderate depression31-40: Severe depression 40: Extreme depression

    Time frame: 0 days

  5. Psychiatric Assessment

    Generalized anxiety disorder (GAD 7 score) will be performed. It has 7 questions. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD

    Time frame: 0 days

  6. Psychiatric Assessment

    Generalized anxiety disorder (GAD 7 score) test will be performed

    Time frame: 30 days

  7. Psychiatric Assessment

    Beck's Depression Inventory (BDI) test will be performed. The scoring is as follows 1-10: These ups and downs are considered normal 11-16: Mild mood disturbance 17-20: Borderline clinical depression 21-30: Moderate depression31-40: Severe depression 40: Extreme depression

    Time frame: 30 days

  8. Psychiatric Assessment

    Beck's Depression Inventory (BDI)test will be performed The scoring is as follows 1-10: These ups and downs are considered normal 11-16: Mild mood disturbance 17-20: Borderline clinical depression 21-30: Moderate depression31-40: Severe depression 40: Extreme depression

    Time frame: 90 days

  9. Psychiatric Assessment

    Generalized anxiety disorder (GAD 7 score) tests will be performed

    Time frame: 90 days

  10. HRQOL will be performed by SF-36

    Health related query of life will be performed.

    Time frame: 0 days

  11. HRQOL will be performed by SF-36

    Health related query of life will be performed.

    Time frame: 30 days

  12. HRQOL will be performed by SF-36

    Health related query of life will be performed.

    Time frame: 90 days

  13. Assessment of changes in ammonia

    Estimation of ammonia by arterial fasting test/ capillary test will be performed

    Time frame: At enrolment

  14. Assessment of changes in ammonia

    Estimation of ammonia by arterial fasting test/ capillary test will be performed

    Time frame: 24 week

  15. Assessment of changes in muscle health

    Estimation of sarcopenia will be performed by muscle ultrasound by SARCUS.

    Time frame: Baseline

  16. Assessment of changes in muscle health

    Estimation of sarcopenia by muscle ultrasound by SARCUS.

    Time frame: 30 days

  17. Assessment of changes in muscle health

    Estimation of sarcopenia by muscle ultrasound by SARCUS.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2025 (actual). Primary completion is estimated for Aug 2027, 30 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Aug 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Aug 5, 2024
StartActual
Feb 1, 2025
Primary completionEst.
Aug 2027was Aug 2026
CompletionEst.
Aug 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Aug 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Aug 2026→Aug 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06538077
Collaborators
Indian Council of Medical Research
Responsible party
Madhumita Premkumar (ASSOCIATE PROFESSOR, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Aug 5, 2024
Start date
Feb 1, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Madhumita Premkumar
Contact
drmadhumitap@gmail.com
+9101722754777

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amino Acids, Branched-Chain · Rifaximin

Start the discussion